1,964 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Purchased by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,964 shares of the company's stock, valued at approximately $602,000.

Other hedge funds have also made changes to their positions in the company. Portside Wealth Group LLC boosted its stake in shares of Medpace by 14.8% during the fourth quarter. Portside Wealth Group LLC now owns 1,419 shares of the company's stock worth $435,000 after buying an additional 183 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in Medpace by 355.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,555 shares of the company's stock valued at $1,090,000 after purchasing an additional 2,774 shares during the period. Chase Investment Counsel Corp lifted its position in Medpace by 3.2% in the third quarter. Chase Investment Counsel Corp now owns 9,849 shares of the company's stock valued at $2,384,000 after purchasing an additional 301 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its position in Medpace by 42.7% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 19,920 shares of the company's stock valued at $4,823,000 after purchasing an additional 5,956 shares during the period. Finally, Federated Hermes Inc. lifted its position in Medpace by 164.6% in the third quarter. Federated Hermes Inc. now owns 29,075 shares of the company's stock valued at $7,040,000 after purchasing an additional 18,088 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on MEDP. Deutsche Bank Aktiengesellschaft began coverage on shares of Medpace in a research report on Monday, March 18th. They issued a "hold" rating and a $395.00 price objective for the company. StockNews.com downgraded shares of Medpace from a "buy" rating to a "hold" rating in a research report on Saturday, March 23rd. UBS Group upgraded shares of Medpace from a "neutral" rating to a "buy" rating and raised their price objective for the company from $282.00 to $452.00 in a research report on Thursday, February 15th. Finally, Robert W. Baird increased their target price on shares of Medpace from $312.00 to $408.00 and gave the company an "outperform" rating in a report on Wednesday, February 14th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $382.00.

Insider Transactions at Medpace

In other news, CEO August J. Troendle sold 100,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the transaction, the chief executive officer now directly owns 4,833,019 shares of the company's stock, valued at approximately $1,995,940,186.62. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Medpace news, major shareholder Medpace Investors, Llc sold 50,000 shares of Medpace stock in a transaction on Friday, February 16th. The shares were sold at an average price of $391.75, for a total value of $19,587,500.00. Following the transaction, the insider now owns 5,539,947 shares in the company, valued at approximately $2,170,274,237.25. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO August J. Troendle sold 100,000 shares of Medpace stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the transaction, the chief executive officer now owns 4,833,019 shares in the company, valued at approximately $1,995,940,186.62. The disclosure for this sale can be found here. Insiders sold a total of 189,340 shares of company stock valued at $76,651,647 in the last ninety days. Corporate insiders own 20.30% of the company's stock.

Medpace Price Performance

Medpace stock traded down $2.61 during mid-day trading on Wednesday, reaching $382.44. The company had a trading volume of 212,271 shares, compared to its average volume of 240,902. Medpace Holdings, Inc. has a 1 year low of $185.43 and a 1 year high of $419.42. The company has a market capitalization of $11.85 billion, a P/E ratio of 43.36, a P/E/G ratio of 2.05 and a beta of 1.38. The stock's 50-day simple moving average is $392.28 and its 200-day simple moving average is $318.22.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, February 12th. The company reported $2.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.22 by $0.24. Medpace had a net margin of 15.00% and a return on equity of 63.98%. The company had revenue of $498.40 million during the quarter, compared to analysts' expectations of $498.72 million. During the same period last year, the company posted $2.12 earnings per share. The firm's quarterly revenue was up 26.5% compared to the same quarter last year. On average, equities analysts forecast that Medpace Holdings, Inc. will post 10.53 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.